Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05361174 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
A Phase 1 study of Metastatic Melanoma and Unresectable Melanoma, sponsored by Iovance Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 10
- Study locations
NCT05361174 is a Phase 1 study of Metastatic Melanoma and Unresectable Melanoma that is actively recruiting participants, run by Iovance Biotherapeutics. The registered enrollment target is 53 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (36% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT05361174, a Phase 1 study of Metastatic Melanoma and Unresectable Melanoma, is actively recruiting participants, sponsored by Iovance Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Conditions Studied
Interventions
- BIOLOGICAL IOV-4001
Study Locations (10)
Florida
- Sylvester Comprehensive Cancer Center - Miami
- Orlando Health Cancer Institute - Orlando
- Moffitt Cancer Center - Tampa
California
- The Angeles Clinic and Research Institute - Los Angeles
Kansas
- The University of Kansas Cancer Center - Westwood
Kentucky
- University of Louisville - Louisville
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- University of Cincinnati - Cincinnati
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-07-20 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05361174
The ClinicalTrials.gov registry entry for NCT05361174 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (36% lower). The listed sponsor is Iovance Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which IOV-4001 is the first listed.
NCT05361174 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Kansas.
Frequently Asked Questions
What is clinical trial NCT05361174 about?
NCT05361174 is a clinical study titled "A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer". This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
What is the current status of trial NCT05361174?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2022-07-20. Estimated completion is 2027-06.
What conditions does trial NCT05361174 study?
This clinical trial studies the following conditions: Metastatic Melanoma, Unresectable Melanoma, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT05361174?
The interventions under investigation include: IOV-4001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05361174?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05361174 being conducted?
This trial has 10 study locations across California, Florida, Kansas, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RECRUITING · Phase 1
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.